Answers are grounded in this paper and cite their sources.
Preclinical in vitro study demonstrates potent antitubercular and antibacterial activity of novel imidazolinone–benzenesulfonamide derivatives, suggesting potential for new antimicrobial drug...
A novel series of imidazolinone–benzenesulfonamide derivatives was designed and synthesized to investigate their antibacterial and antitubercular potential. The target compounds were prepared via a multistep synthetic strategy involving the construction of the imidazolinone core followed by sulfonamide coupling with suitably substituted aromatic amines. The synthesized compounds were fully characterized using spectroscopic techniques, including IR, 1H NMR, 13C NMR, and mass spectrometry. The antibacterial activity was evaluated against three Gram-positive and four Gram-negative bacterial strains, namely Bacillus subtilis (NCIM 2698), Micrococcus varians (NCIM 2913), Staphylococcus aureus (NCIM 2079), Escherichia coli (NCIM 2344), Klebsiella pneumoniae (NCIM 2957), Pseudomonas fluorescens (NCIM 2639), and Serratia marcescens (NCIM 2919), using the disc diffusion method with gentamicin as the reference drug. Antitubercular activity was assessed by the microplate Alamar blue assay (MABA) against Mycobacterium tuberculosis H37Rv, with pyrazinamide as the positive control. The synthesized compounds demonstrated excellent antitubercular activity and good antibacterial efficacy. Substituents such as chloro and methoxy groups were found to significantly enhance antitubercular activity. Further in vivo studies are warranted to evaluate their therapeutic potential.
No takes yet. Share an insight, caveat, or question.
Ghnaim et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: